PMID- 36066750
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220928
IS  - 2198-6576 (Print)
IS  - 2198-6584 (Electronic)
IS  - 2198-6576 (Linking)
VI  - 9
IP  - 5
DP  - 2022 Oct
TI  - Ustekinumab Is Rapid-Acting and Is an Effective Long-Term Treatment for Patients 
      with Active Psoriatic Arthritis: Real-World Evidence from the Non-interventional 
      SUSTAIN Study.
PG  - 1435-1450
LID - 10.1007/s40744-022-00484-3 [doi]
AB  - INTRODUCTION: Psoriatic arthritis (PsA) is a chronic, progressive disease that 
      places a significant burden on patients and healthcare systems. The SUSTAIN study 
      collected real-world evidence on long-term effectiveness, impact on quality of 
      life, and safety of ustekinumab treatment for PsA. METHODS: SUSTAIN was a 
      prospective, non-interventional study conducted in Germany. Patients with active 
      PsA received ustekinumab for 160 weeks in routine clinical care, with assessments 
      at baseline, week 4, and every 12 weeks thereafter. This analysis focuses on 
      patients who remained in SUSTAIN until week 160. RESULTS: Of 337 patients 
      enrolled, 129 were documented at week 160, of which 123 (95.3%) had received 
      previous PsA medication, including biologics. Decreases from baseline to week 4 
      were observed for tender joint count (TJC, 8.0 to 5.8) and swollen joint count 
      (SJC, 4.5 to 3.1); these decreases continued to week 28 and were maintained to 
      week 160 (1.0 and 0.4, respectively). Similarly, skin assessments in patients 
      with PsA and psoriasis revealed improvement at week 4, which continued to week 
      28, with a sustained effect until week 160. Similar patterns of response were 
      observed for patient-assessed pain, sleep quality, and health scores. 
      Improvements in TJC, SJC, Psoriasis Area and Severity Index, and affected body 
      surface area were observed irrespective of the number of prior biologic therapies 
      used. Minimal disease activity was achieved by 36 (31.9%) patients at week 28, 
      and by 38 (33.6%) at week 52. Ustekinumab-related adverse events (AEs) and 
      serious AEs were reported in 61 (47.3%) and 4 (3.1%) patients, respectively. At 
      week 160, 100% of patients assessed ustekinumab tolerability as good or very 
      good. CONCLUSIONS: In a real-world setting, patients with active PsA who received 
      ustekinumab until 160 weeks (3 years), including those who received prior 
      biologic therapies, had a rapid onset of effect and sustained response to 
      treatment, with high tolerability. TRIAL REGISTRATION: PEI NIS No. 290.
CI  - (c) 2022. The Author(s).
FAU - Wendler, Jorg
AU  - Wendler J
AD  - Rheumatologische Schwerpunktpraxis, Erlangen, Germany.
FAU - Damann, Nils
AU  - Damann N
AUID- ORCID: 0000-0002-6117-6769
AD  - Janssen-Cilag, Neuss, Germany. NDamann@its.jnj.com.
FAU - Rocken, Marit
AU  - Rocken M
AD  - Janssen-Cilag, Neuss, Germany.
FAU - Teicher, Verena
AU  - Teicher V
AD  - Janssen-Cilag, Neuss, Germany.
FAU - Schuier, Maximilian
AU  - Schuier M
AD  - Janssen-Cilag, Neuss, Germany.
FAU - Hamann, Frank
AU  - Hamann F
AD  - Gemeinschaftspraxis fur Internistische Rheumatologie, Leipzig, Germany.
FAU - Schwenke, Holger
AU  - Schwenke H
AD  - Rheumatologisches MVZ, Dresden, Germany.
FAU - Sieburg, Maren
AU  - Sieburg M
AD  - Rheumatologische Facharztpraxis, Magdeburg, Germany.
FAU - Behrens, Frank
AU  - Behrens F
AD  - Rheumatologie und Fraunhofer Institut IM-TMP, Goethe-Universitat, Frankfurt, 
      Germany.
LA  - eng
PT  - Journal Article
DEP - 20220906
PL  - England
TA  - Rheumatol Ther
JT  - Rheumatology and therapy
JID - 101674543
PMC - PMC9510084
OTO - NOTNLM
OT  - Long-term efficacy
OT  - Psoriatic arthritis
OT  - Real world
OT  - Tolerability
OT  - Ustekinumab
COIS- Jorg Wendler was an advisor and/or received speakers' honoraria and/or received 
      grants and/or participated in clinical trials of the following companies: AbbVie, 
      Chugai, Janssen-Cilag GmbH, Novartis, Roche Pharma; Nils Damann, Marit Rocken, 
      and Verena Teicher are employees of Janssen-Cilag GmbH and hold stocks of Johnson 
      & Johnson; Maximilian Schuier is an employee of Johnson & Johnson, holding stocks 
      thereof; Frank Hamann, Holger Schwenke, and Maren Sieburg declare no competing 
      interests; Frank Behrens has received research grants and consultancy/speaker 
      fees from Janssen.
EDAT- 2022/09/07 06:00
MHDA- 2022/09/07 06:01
PMCR- 2022/09/06
CRDT- 2022/09/06 11:19
PHST- 2022/06/01 00:00 [received]
PHST- 2022/08/12 00:00 [accepted]
PHST- 2022/09/07 06:00 [pubmed]
PHST- 2022/09/07 06:01 [medline]
PHST- 2022/09/06 11:19 [entrez]
PHST- 2022/09/06 00:00 [pmc-release]
AID - 10.1007/s40744-022-00484-3 [pii]
AID - 484 [pii]
AID - 10.1007/s40744-022-00484-3 [doi]
PST - ppublish
SO  - Rheumatol Ther. 2022 Oct;9(5):1435-1450. doi: 10.1007/s40744-022-00484-3. Epub 
      2022 Sep 6.